Coherus Oncology, Inc. (CHRS)
Biological Products, (No Diagnostic Substances) · Healthcare · $231M
Intrinsic Value (Consensus)
$0.00
Current Price
$1.50
Margin of Safety
0%
At Fair Value
Value: $0
Price: $2
Valuation Model Estimates
Current Price: $1.50
DCF (Discounted Cash Flow)
$21.58
Graham Number
$4.34
Earnings Power Value
$16.51
Relative Value (P/E)
$33.32
Dividend Discount Model
Not applicable
—
Consensus Value
$0.00
Model Assumptions
Discount Rate
10.3%
Growth Rate
5.0%
Terminal Growth
2.5%
Risk-Free Rate
4.3%
Discount rate derived from CAPM (risk-free rate + beta × market risk premium). Growth rate based on trailing earnings growth, capped at 20%.
Health Score
C
56
Profitability
25/25
Strength
6/25
Valuation
12/25
Growth
13/25
Financial Health Signals
Negative free cash flow — company is burning cash
Elevated debt — Debt/Equity ratio is 121%
Strong profitability — ROE of 275% (above 20% is excellent)
Key Financials
- EPS (TTM)
- $1.67
- EPS (Forward)
- $1.75
- Book Value
- $0.50
- P/E Ratio
- 20.0
- Forward P/E
- 16.7
- PEG Ratio
- —
- ROE
- 275.4%
- Debt/Equity
- 121%
- Revenue Growth
- 10.9%
- Earnings Growth
- 5.0%
- Dividend Yield
- N/A
- Beta
- 0.96
Similar Stocks (Healthcare)
ABEOAbeona Therapeutics ...
$37.06+300%
ABUSArbutus Biopharma Co...
$18.93+300%
ADVBAdvanced Biomed Inc....
$26.66+300%
AGENAgenus Inc.
$20.19+300%
ATRAAtara Biotherapeutic...
$41.43+300%
Data last updated: 2026-06-21
Source: Yahoo Finance